MP Healthcare Venture Management

Connecting ideas, technologies, and business processes


    MPH is a venture capital firm that invests in innovative research-driven companies in the areas of biotechnology, therapeutics and vaccines. Founded in 2006, MPH is a subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). By working with MPH, promising companies can gain access to the funding and industry expertise needed to bring state-of-the-art products to market. MPH invests in companies developing novel therapeutics, platform technologies, diagnostics, and vaccines. MPH is interested in novel drugs in broad disease areas including neuroscience (particularly neurodegeneration), immunology, inflammation, and rare disease, as well as diagnostics for neurodegenerative disorders. Current platform technology areas of interest include regenerative medicine, synthetic biology, microbiome, gene therapy, and nucleic acid medicine.